clinical trial · NCT07092748
A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors
Zhejiang Hisun Pharmaceutical Co. Ltd.·phase1·recruiting·n = 110
Advanced Solid CancersHS387
brief summary
This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and preliminary efficacy of HS387 in subjects with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and the dose expansion study (Phase Ib)
started
Jul 15, 2025
primary completion
Jun 30, 2028
completion
Dec 31, 2028
last updated
Jul 30, 2025
official title
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HS387 in Subjects With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol